What this archive is

What this archive holds

Peptides Foundation is a research archive built around peptides that carry real clinical and preclinical data. It holds four compounds — tesamorelin, semaglutide, thymosin alpha-1, and PT-141 — chosen not because they are the most used or the most talked-about, but because each has a published controlled-trial record substantial enough to read closely and report accurately.

Everything here is a reading of publicly available research, kept plain and sourced. It is not a store; it is not a clinic; it dispenses no medical advice, recommends no doses, and opens no path to obtaining any compound. The word 'Foundation' names the idea of building understanding on solid clinical footings — not a registered nonprofit, charity, or institution. No charitable status is claimed, and there is no membership, no grant-making, and no organizational body behind the archive.

How the archive is sourced

What the archive admits is deliberately narrow: peer-reviewed journals (PubMed-indexed or equivalent); regulatory documents from the FDA and its counterparts; NIH-hosted monographs (LiverTox, DrugBank, ClinicalTrials.gov); and systematic reviews or meta-analyses of the above. Every factual claim is cited by number to a specific source in the references index.

The reading follows a set standard: lead with what is not established, flag single-lab or preclinical-only findings outright, name the study population where it limits generalizability (as with tesamorelin's HIV-specific trial base), and file null results with the same weight as positive ones (as with the 2025 TESTS sepsis trial for thymosin alpha-1 ^[13]). The aim is accuracy, not optimism.

Community-reported anecdotal effects are shelved on compound pages under a clear 'anecdotal, not clinical evidence' label — they are part of the real-world landscape around these compounds, and leaving them out would be its own distortion. They are never dressed as clinical findings.

Standing and limits

The archive holds no commercial relationship with any supplier, clinic, pharmaceutical company, or research organization touching the compounds described here. It carries no advertising and takes no industry funding.

A few limits worth stating: this is not a substitute for medical consultation. It assesses no individual's health condition, knows no reader's history, and cannot decide whether any compound is safe or right for a specific person. None of the four should be approached without a qualified clinician — the more so because three are FDA-approved drugs requiring a prescription, and the fourth (thymosin alpha-1) is a non-US-approved compound reachable in the US only through investigational or compounding channels.

Holdings are updated as significant new evidence appears. Each cited study's publication date sits in the references index so readers can judge currency for themselves.